PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

Read More on BCSF: M&A News: Bain Capital Buys 350-Year-Old Japanese Drugs Firm for $3.4 billion KKR Hikes Offer Price for Fuji Soft in Ongoing Battle With Rival Bain ...

Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

KKR has extended its tender offer for FUJI SOFT to January 24, 2025, amid Bain Capital's hostile bid, reaffirming its commitment to privatizing the company.

TOKYO (Reuters) - U.S. private equity firm Bain Capital said on Monday it will not launch a tender offer for Fuji Soft, formally ending a takeover battle with rival KKR for the Japanese IT company.